FDA rules against Tysabri warning; Merck CEO isn't sweating the new HPV vax competition;

> The FDA says that Biogen Idec and Elan Corp's multiple sclerosis blockbuster Tysabri does not require new warnings despite a rise in the number of cases of a potentially brain infection. Article

> The long-awaited endorsement of GlaxoSmithKline's HPV vaccine Cervarix is widely expected to pave a short path to formal FDA approval. But Merck isn't sounding all that concerned that its vaccine, Gardasil, will finally face head-to-head competition in the world's richest drug market. Item

> The FDA sent Allergan a warning over its website for its eyelash thickener Latisse. The agency says the site is misleading because it avoids or downplays risks associated with the product. Article

> Johnson & Johnson and Elan have closed the deal under which J&J's newly formed unit Janssen Alzheimer Immunotherapy acquired all the assets and rights related to Elan's Alzheimer's Immunotherapy Program (AIP). Article

> GlaxoSmithKline is making its drugs more accessible by allowing patients to apply on their own rather than through a healthcare advocate. Article 

Biotech News

> Is the biotech venture glass half empty or half full? Report

> A mystery bidder has pulled out of buyout talks with the UK's Renovo, and the anti-scarring drug developer has responded by laying plans to slash more than a third of its staff of about 180. Report

> Cambridge, MA-based Seaside Therapeutics is emerging from stealth mode this morning with an announcement that it has raised $30 million to pursue mid-stage clinical trial development on new therapies for Fragile X Syndrome and autism. Article

> IPO activity in the biotech arena continues to heat up with the news that Omeros filed to sell 6.8 million shares for up to $81.6 million. IPO report

Vaccine News

> A federal judge has tossed Emergent BioSolutions' attempt to force Protein Sciences into bankruptcy, but Emergent isn't about to give up on its long-running fight with Protein Sciences following the collapse of their merger deal. Report

> Once public health officials start their mass swine flu vaccination campaigns in October, they'll be bracing for a deluge of complaints about adverse events--most of which won't have anything to do with the vaccine. Report

> Adjuvant vaccines developer Juvaris BioTherapeutics has completed the first close of a Series B round. Juvaris news

And Finally... An experimental gene therapy proved effective in spurring full color vision in monkeys that had never before been able to tell green from red. And the same approach could treat color blindness and other ailments in people. Report